New platform aims to predict which cancer treatments will work

NCT ID NCT06349642

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 20 times

Summary

This study collects tissue samples from people with various advanced or early-stage cancers to train a new diagnostic platform called Elephas. The goal is to see how accurately the platform can predict whether a patient's tumor will respond to immunotherapy or chemoimmunotherapy. About 324 participants will provide tissue, and the results will help develop a tool to guide future treatment decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Arizona

    RECRUITING

    Phoenix, Arizona, 85054, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.